Dergiler / Kocatepe Tıp Dergisi / 2006 / Cilt: 7 Sayı: 3

Obezite ve Obezitenin Genetigi

Sayfa
1–11
Yayın Tarihi
2006-12-01
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Poligenik kalitim, multifaktöryel kalıtım modeli gösteren formları ise en yaygın versiyonudur ve genler, çevre, davranış ve hepsinin birbiriyle etkileşiminin bir sonucudur

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Obezite, kalp-damar hastalıkları ve Tip 2 diabet gibi komplikasyonlarıyla birlikte yüzyılımızda epidemik sınırlara yaklaşmaktadır.
📊
Temel Bulgular & Veri:Günümüzde etkin bir tedavisi olmayan obezite, ciddi bir halk sağlığı problemidir.
💡
Sonuç & Katkı:Poligenik kalitim, multifaktöryel kalıtım modeli gösteren formları ise en yaygın versiyonudur ve genler, çevre, davranış ve hepsinin birbiriyle etkileşiminin bir sonucudur
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Obezite · obezite genetigi · Melanocortin sistemi

Özet

Obezite, kalp-damar hastalıkları ve Tip 2 diabet gibi komplikasyonlarıyla birlikte yüzyılımızda epidemik sınırlara yaklaşmaktadır. Günümüzde etkin bir tedavisi olmayan obezite, ciddi bir halk sağlığı problemidir. Obezite pozitif enerji bakiyesi sonucu ortaya çıkar ve genellikle beden kitle indeksi (BMI) ile ölçülür. İnsanlarda obezite ya monogenik sendromlar olarak veya multifaktöryel kalıtım modeline uymaktadirlar. Obezitenin monogenik versiyonları Leptin (LEP), Leptin reseptörü (LEPR), Melanocortin 4 reseptörü (MC4R) gibi belli genlerdeki mutasyonlar sonucu ortaya çıkar. Bunların sıklığı toplam olguların çok az bir kısmını oluşturur. Poligenik kalitim, multifaktöryel kalıtım modeli gösteren formları ise en yaygın versiyonudur ve genler, çevre, davranış ve hepsinin birbiriyle etkileşiminin bir sonucudur

🔖

Bu Makaleye Atıf Yap

Sozen, M. A. (2006). Obezite ve Obezitenin Genetigi. Kocatepe Tıp Dergisi, Cilt: 7 Sayı: 3, 1–11. https://doi.org/10.18229/ktd.69200

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (273)

  1. Friedman JM. Obesity in the new millennium. Nature
  2. Apr 61404 (6778):632-4.
  3. http://www.cdc.gov/nchs/about/major/nhanes/
  4. Kuczmarski RJ, Flegal KM. CDC growth charts:
  5. JA, Dwarki VJ. Long-term correction of obesity and
  6. diabetes in genetically obese mice by a single
  7. intramuscular injection of recombinant adeno
  8. associated virus encoding mouse leptin. Proc Natl
  9. Acad Sci U S A. 1997 Dec 9;94(25):13921-6.). Huszar D, Lynch CA, Fairchild-Huntress V,
  10. Dunmore JH, Fang Q, Berkemeier LR, Gu W,
  11. Kesterson RA, Boston BA, Cone RD, Smith FJ,
  12. CampŞeld LA, Burn P, Lee F. Targeted disruption of
  13. the melanocortin-4 receptor results in obesity in mice.
  14. Cell. 1997 Jan 10;88(1):13l-41. Chen AS, Metzger JM, Trumbauer ME, Guan XM,
  15. Yu H, Frazier EG, Marsh DJ, Forrest MJ, Gopal
  16. Truter S, Fisher J, Camacho RE, Strack AM, Mellin
  17. TN, Maclntyre DE, Chen HY, Van der Ploeg LH. Ro—
  18. le of the melanocortin-4 receptor in metabolic rate
  19. and food intake in mice. Transgenic Res. 2000
  20. Apr;9(2):145-54. Butler AA, Marks DL. Fan W, Kuhn CM, Bartolome
  21. Invest. 2005 Dec;115(12):3573—8. Zigman JM, Nakano Y, Coppari R, Balthasar N.
  22. Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman
  23. AR, White RD, Williams TD, Lachey JL, Seeley RJ,
  24. Lowell BB, Elmquist JK. Mice lacking ghrelin
  25. receptors resist the development of diet-induced
  26. obesity. J Clin Invest. 2005 Dec;115(12):3564-72. Lechan RM, Tatro JB. Hypothalamic melanocortin
  27. signaling in cachexia. Endocrinology. 2001
  28. Aug;142(8):3288-91. Review. No abstract available. Broberger C, Johansen J, Brismar H, Johansson C,
  29. Schalling M, Hokfelt T. Changes in neuropeptide Y
  30. receptors and pro-opiomelanocortin in the anorexia
  31. (anx/anx) mouse hypothalamus. J Neurosci, 1999
  32. Aug 15;19(l6):7130-9. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ,
  33. Argyropoulos G, Walts B, Perusse L, Bouchard C.
  34. The human obesity gene map: the 2005 update.
  35. S A. 2005 Apr 26;102(17):6207-12. Epub 2005 Apr 15. Barsh GS, Ollmann MM, Wilson BD, Miller KA,
  36. Gunn TM. Molecular pharmacology of Agouti prote
  37. in in vitro and in vivo. Ann N Y Acad Sci. 1999 Oct;885:143—52. Review. Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS.
  38. Interaction of Agouti protein with the melanocortin 1
  39. receptor in vitro and in vivo. Genes Dev. 1998 Feb;12(3):316-30. Ollmann MM, Wilson BD, Yang YK, Kerns JA,
  40. Chen Y, Gantz I, Barsh GS. Antagonism of central
  41. melanocortin receptors in vitro and in vivo by agouti—
  42. related protein. Science. 1997 Oct 3;278(5335):l35—8.
  43. Erratum in: Science 1998 Sep ll;281(5383):1615. Stutz AM, Morrison CD, Argyropoulos G. The
  44. Agouti—related protein and its role in energy homeostasis. Gantz 1, Fong TM. The melanocortin system. Am J
  45. Physiol Endocrinol Metab. 2003 Mar;284(3):E468- 74. Review. Bemdt C, Casaroli-Marano RP, Vilaro S, Reina M.
  46. Cloning and characterization of human syndecan—3. J
  47. Cell Biochem. 2001; 82(2): 246-59. Ha E, Kim MJ, Choi BK, Rho JJ, Oh DJ, Rho TH,
  48. Kim KH, Lee HJ, Shin DH, Yim SV, Baik HH,
  49. Chung JH, Kim JW. Positive association of obesity
  50. with single nucleotide polymorphisms of syndecan 3
  51. in the Korean population. J Clin Endocrinol Metab.
  52. Dec;9l(l2):5095-9. Epub 2006 Oct 3. Nagle DL, McGrail SH, Vitale J, Woolf EA, Dussault
  53. BJ Jr, DiRocco L, Holmgren L, Montagno J, Bork P,
  54. Huszar D, Fairchild—Huntress V, Ge P, Keilty J,
  55. Ebeling C, Baldini L, Gilchrist J, Burn P, Carlson
  56. GA, Moore KJ. The mahogany protein is a receptor
  57. involved in suppression of obesity. Nature. 1999 Mar
  58. ll;398(6723):l48-52. Tang W, Gunn TM, McLaughlin DF, Barsh GS,
  59. Schlossman SF, Duke-Cohan JS. Secreted and
  60. membrane attractin result from alternative splicing of
  61. the human ATRN gene. Proc Natl Acad Sci U S A.
  62. May 23;97(11):6025-30. Wilson BD, Bagnol D, Kaelin CB, Ollmann MM,
  63. Gantz l, Watson SJ, Barsh GS. Physiological and
  64. anatomical circuitry between Agouti-related protein
  65. and leptin signaling. Endocrinology. 1999
  66. May;l40(5):2387—97. Cowley MA, Smart JL, Rubinstein M, Cerdan MG,
  67. Diano S, Horvath TL, Cone RD, Low MJ. Leptin
  68. activates anorexigenic POMC neurons through a
  69. neural network in the arcuate nucleus. Nature. 2001
  70. May 24;4l l(6836):480-4. 57. Cowley MA. Hypothalamic melanocortin neurons integrate signals of energy state. Eur J Phannacol.
  71. Nov 7;480(1-3):3-1 1. Review. Heisler LK, Cowley MA, Tecott LH, Fan W, Low
  72. MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN,
  73. Holstege H, Lee CE, Cone RD, Elmquist JK.
  74. Activation of central melanocortin pathways by
  75. fenşuramine. Science. 2002 Jul 26;297(5581):609- 11. Heisler LK, Jobst EE, Sutton GM, Zhou L, Borok E,
  76. Thornton-Jones Z, Liu HY, Zigman JM, Balthasar N,
  77. Kishi T, Lee CE, Aschkenasi CJ, Zhang CY, Yu J,
  78. Boss O, Mountjoy KG, CliŞon PG, Lowell BB,
  79. Friedman JM, Horvath T, Butler AA, Elmquist JK,
  80. Cowley MA. Serotonin reciprocally regulates
  81. melanocortin neurons to modulate food intake.
  82. Neuron. 2006 Jul 20;51(2):239-49. Munzberg H, Jobst EE, Bates SH, Jones J, Villanueva
  83. E, Leshan R, Bjomholm M, Elmquist J, Sleeman M,
  84. Cowley MA, Myers MG Jr. Appropriate inhibition of
  85. orexigenic hypothalamic arcuate nucleus neurons
  86. independently of leptin receptor/STAT3 signaling. J
  87. Neurosci. 2007 Jan 3;27(l):69-74. LEP. Fulu Bai, Mehmet Ali Sözen, Walter J. Lukiw, George
  88. Argyropoulos. Expression of AgRP, NPY, POMC, and
  89. CART by human fetal and adult hippocampus.
  90. Neuropeptides. 2005 Aug; 39(4):439—43. Savontaus E, Conwell IM, Wardlaw SL. Effects of
  91. adrenalectomy on AGRP, POMC, NPY and CART
  92. gene expression in the basal hypothalamus of fed and
  93. fasted rats. Brain Res. 2002 Dec 20;958(l):l30-8. Bertile F, Oudart H, Criscuolo F, Maho YL, Raclot T.
  94. Hypothalamic gene expression in long-term fasted
  95. rats: relationship with body fat. Biochem Biophys
  96. Res Commun. 2003 Apr 18;303(4):1 106-13. Tritos NA, Mantzoros CS. Leptin: its role in obesity
  97. and beyond. Diabetologia. 1997 Dec;40( 12): 1371-9. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R,
  98. Winters D, Boone T, Collins F. Effects of the obese
  99. gene product on body weight regulation in ob/ob
  100. mice. Science. 1995 Jul 28;269(5223):540-3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold
  101. L, Friedman JM. Positional cloning of the mouse
  102. obese gene and its human homologue. Nature;372:425-32. Hager J, Clement K, Francke S, Dina C, Raison J,
  103. Lahlou N, Rich N, Pelloux V, Basdevant A, Guy
  104. Grand B, North M, Froguel P. A polymorphism in the
  105. ' untranslated region of the human ob gene is
  106. associated with low leptin levels. Int J Obes Relat
  107. Metab Disord. 1998 Mar;22(3):200-5. CampŞeld LA, Smith FJ, Guisez Y, Devos R, Burn P.
  108. Recombinant mouse OB protein: evidence for a
  109. peripheral signal linking adiposity and central neural
  110. Kocmupu Tıp Dergisi. Cil 7 M): 3. Ei'lr'i/ 3006. SÖZEN ve ark. networks. Science. 1995 Jul 28;269(5223):546-9. LA
  111. CampŞeld 1995 Science. Chung WK, BelŞ K, Chua M, Wiley J, Mackintosh
  112. R, Nicolson M, Boozer CN, Leibel RL.
  113. Heterozygosity for Lep(ob) or Lep(rdb) affects body
  114. composition and leptin homeostasis in adult mice.
  115. Am J Physiol. 1998 Apr;274(4 Pt 2):R985-90. Stefan N, Vozarova B, Del Parigi A, Ossowski V,
  116. Thompson DB, Hanson RL, Ravussin E, Tataranni
  117. PA. The G1n223Arg polymorphism of the leptin
  118. receptor in Pima Indians: inşuence on energy
  119. expenditure, physical activity and lipid metabolism.
  120. Int J Obes Relat Metab Disord. 2002
  121. Dec;26(12):1629-32. Yiannakouris N, Yannakoulia M, Melistas L, Chan
  122. JL, Klimis-Zacas D, Mantzoros CS. The Q223R
  123. polymorphism of the leptin receptor gene is
  124. signiŞcantly associated with obesity and predicts a
  125. small percentage of body weight and body
  126. composition variability. J Clin Endocrinol Metab.
  127. Sep;86(9):4434-9. Jackson RS, Creemers JW, Ohagi S, RafŞn-Sanson
  128. ML, Sanders L, Montague CT, Hutton JC, O’Rahilly
  129. S. Obesity and impaired prohormone processing
  130. associated with mutations in the human prohormone
  131. convertase 1 gene. Nat Genet. 1997 Jul;16(3):303-6. Krude H, Biebermann H, Luck W, Horn R, Brabant
  132. G, Gruters A. Severe early-onset obesity, adrenal
  133. insufŞciency and red hair pigmentation caused by
  134. POMC mutations in humans. Nat Genet. 1998
  135. Jun;19(2):155-7. Adan RA, Tiesjema B, Hillebrand JJ, 1a Fleur SE,
  136. Kas MJ, de Krom M. The MC4 receptor and control
  137. of appetite. Br J Pharmacol. 2006 Dec; l49(7):815
  138. Epub 2006 Oct 16. Vaisse C, Clement K, Guy—Grand B, Froguel P. A
  139. frameshift mutation in human MC4R is associated
  140. with a dominant form of obesity. Nat Genet. 1998
  141. Oct; 20(2): 1 13—4. No abstract available. Vaisse C, Clement K, Durand E, Hercberg S, Guy
  142. Grand B, Froguel P. Melanocortin—4 receptor
  143. mutations are a frequent and heterogeneous cause of
  144. morbid obesity. J Clin Invest. 2000 Jul; 106(2):253- 62. Mergen M, Mergen H, Ozata M, Oner R, Oner C. A
  145. novel melanocortin 4 receptor (MC4R) gene mutation
  146. associated with morbid obesity. J Clin Endocrinol
  147. Metab. 2001 Jul;86(7):3448. Ma L, Tataranni PA, Bogardus C, Baier LJ.
  148. Melanocortin 4 receptor gene variation is associated
  149. with severe obesity in Pima Indians. Diabetes. 2004
  150. Oct; 53(10):2696-9. Valli-Jaakola K, Lipsanen-Nyman M, Oksanen L,
  151. Hollenberg AN, Kontula K, Bjorbaek C, Schalin
  152. Kocatepe Tıp Dergisi, Cilt 7No: 3, Eylül 2006.
  153. Jantti C. IdentiŞcation and characterization of
  154. melanocortin-4 receptor gene mutations in morbidly
  155. obese Şnnish children and adults. J Clin Endocrinol
  156. Metab. 2004 F eb;89(2):940—5. Lubrano-Berthelier C, Cavazos M, Dubem B, Shapiro
  157. A, Stunff CL, Zhang S, Picart F, Govaerts C, Froguel
  158. P, Bougneres P, Clement K, Vaisse C. Molecular
  159. genetics of human obesity-associated MC4R
  160. mutations. Ann N Y Acad Sci. 2003 Jun;994:49-57. Review. Srinivasan S, Lubrano-Berthelier C, Govaerts C,
  161. Picard F, Santiago P, Conklin BR, Vaisse C.
  162. Constitutive activity of the melanocortin-4 receptor is
  163. maintained by its N—terminal domain and plays a role
  164. in energy homeostasis in humans. J Clin Invest. 2004
  165. Oct;114(8):1158-64. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy
  166. R, Stark KL. Hypothalamic expression of ART, 3
  167. novel gene related to agouti, is up—regulated in obese
  168. and diabetic mutant mice. Genes Dev. 1997 Mar;11(5):593-602.Brown AM, Mayfield DK, Volaufova J,
  169. Argyropoulos G. The gene structure and minimal
  170. promoter of the human agouti related protein. Gene.
  171. Oct 17;277(1—2):231-8. Beltramo M, Campanella M, Tarozzo G, Fredduzzi S,
  172. Corradini L, F orlani A, Bertorelli R, Reggiani A. Ge
  173. ne expression proŞling of melanocortin system in
  174. neuropathic rats supports a role in nociception. Brain
  175. Res Mol Brain Res. 2003 Oct 21,1 18(1—2):111-8. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark
  176. KL. Overexpression of Agrt leads to obesity in
  177. transgenic mice. Nat Genet. 1997 Nov; 17(3): 273-4.
  178. No abstract available. Lu XY, Nicholson JR, Akil H, Watson SJ. Time
  179. course of short-term and long-term orexigenic effects
  180. of Agouti-related protein (86—132). Neuroreport. 2001
  181. May 8; 12(6): 1281—4. Small CJ, Liu YL, Stanley SA, Connoley IP,
  182. Kennedy A, Stock MJ, Bloom SR. Chronic CNS
  183. administration of Agouti-related protein (Agrp)
  184. reduces energy expenditure. Int J Obes Relat Metab
  185. Disord. 2003 Apr; 27(4):530-3. Goto K, Inui A, Takimoto Y, Yuzuriha H, Asakawa
  186. A, Kawamura Y, Tsuji H, Takahara Y, Takeyama C,
  187. Katsuura G, Kasuga M. Acute intracerebroventricular
  188. administration of either carboxyl-terminal or amino—
  189. terminal fragments of agouti-related peptide produces
  190. a long-term decrease in energy expenditure in rats. Int
  191. J Mol Med. 2003 Sep; 12(3):379-83. Makimura H, Mizuno TM, Mastaitis JW, Agami R,
  192. Mobbs CV. Reducing hypothalamic AGRP by RNA
  193. interference increases metabolic rate and decreases
  194. body weight without inşuencing food intake. BMC
  195. Neurosci. 2002 Nov 73:18. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T,
  196. Weinberg D, Tota MR, Van der Ploeg LH. ART (pro
  197. tein product of agouti-related transcript) as an anta—
  198. gonist of MC-3 and MC-4 receptors. Biochem
  199. Biophys Res Commun. 1997 Aug 28; 237(3):629—31. Yang YK, Thompson DA. Dickinson CJ, Wilken J,
  200. Barsh GS, Kent SB, Gantz 1. Contribution of
  201. melanocortin receptor exoloops to Agouti—related pro
  202. tein binding. J Biol Chem. 1999 May 14;
  203. :14100-6. Argyropoulos G, Rankinen T, Neufeld DR, Rice T,
  204. Province MA, Leon AS, Skinner JS, Wilmore JH,
  205. Rao DC, Bouchard C. A polymorphism in the human
  206. agouti-related protein is associated with late—onset
  207. obesity. J Clin Endocrinol Metab. 2002 Sep;
  208. :4198-202. Bai F, Rankinen T, Charbonneau C, Belsham DD,
  209. Rao DC, Bouchard C, Argyropoulos G. Functional
  210. dimorphism of two hAgRP promoter SNPs in linkage
  211. disequilibrium. J Med Genet. 2004 May;4l(5):350-3. 94. Sozen MA, de Jonge LH, Greenway F, Ravussin E, 95. Vink T, Hinney A, van Elburg AA, van Goozen SH,
  212. Sandkuijl LA, Sinke RJ, Herpertz-Dahlmann BM,
  213. Hebebrand J, Remschmidt H, van Engeland H, Adan
  214. RA. Association between an agouti-related protein
  215. gene polymorphism and anorexia nervosa. Mol
  216. Psychiatry. 2001 May;6(3):325-8. Marks DL, Boucher N, Lanouette CM, Perusse L,
  217. Brookhart G, Comuzzie AG, Chagnon YC, Cone RD.
  218. Ala67Thr polymorphism in the Agouti-related
  219. peptide gene is associated with inherited leanness in
  220. humans. Am J Med Genet A. 2004 Apr 30; 126(3):267-71.
  221. Kocatepe Tıp Dergisi, Cilt 7 No: 3, Eylül 2006.
  222. Apr 61404 (6778):632-4.
  223. Acad Sci U S A. 1997 Dec 9;94(25):13921-6.). Huszar D, Lynch CA, Fairchild-Huntress V,
  224. Cell. 1997 Jan 10;88(1):13l-41. Chen AS, Metzger JM, Trumbauer ME, Guan XM,
  225. Apr;9(2):145-54. Butler AA, Marks DL. Fan W, Kuhn CM, Bartolome
  226. Invest. 2005 Dec;115(12):3573—8. Zigman JM, Nakano Y, Coppari R, Balthasar N.
  227. obesity. J Clin Invest. 2005 Dec;115(12):3564-72. Lechan RM, Tatro JB. Hypothalamic melanocortin
  228. Aug;142(8):3288-91. Review. No abstract available. Broberger C, Johansen J, Brismar H, Johansson C,
  229. Aug 15;19(l6):7130-9. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ,
  230. S A. 2005 Apr 26;102(17):6207-12. Epub 2005 Apr 15. Barsh GS, Ollmann MM, Wilson BD, Miller KA,;885:143—52. Review. Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS.;12(3):316-30. Ollmann MM, Wilson BD, Yang YK, Kerns JA,
  231. Erratum in: Science 1998 Sep ll;281(5383):1615. Stutz AM, Morrison CD, Argyropoulos G. The
  232. Agouti—related protein and its role in energy homeostasis. Gantz 1, Fong TM. The melanocortin system. Am J
  233. Physiol Endocrinol Metab. 2003 Mar;284(3):E468- 74. Review. Bemdt C, Casaroli-Marano RP, Vilaro S, Reina M.
  234. Cell Biochem. 2001; 82(2): 246-59. Ha E, Kim MJ, Choi BK, Rho JJ, Oh DJ, Rho TH,
  235. Dec;9l(l2):5095-9. Epub 2006 Oct 3. Nagle DL, McGrail SH, Vitale J, Woolf EA, Dussault
  236. ll;398(6723):l48-52. Tang W, Gunn TM, McLaughlin DF, Barsh GS,
  237. May 23;97(11):6025-30. Wilson BD, Bagnol D, Kaelin CB, Ollmann MM,
  238. May;l40(5):2387—97. Cowley MA, Smart JL, Rubinstein M, Cerdan MG,
  239. Nov 7;480(1-3):3-1 1. Review. Heisler LK, Cowley MA, Tecott LH, Fan W, Low
  240. fenşuramine. Science. 2002 Jul 26;297(5581):609- 11. Heisler LK, Jobst EE, Sutton GM, Zhou L, Borok E,
  241. Neuron. 2006 Jul 20;51(2):239-49. Munzberg H, Jobst EE, Bates SH, Jones J, Villanueva
  242. Neurosci. 2007 Jan 3;27(l):69-74. LEP. Fulu Bai, Mehmet Ali Sözen, Walter J. Lukiw, George
  243. Neuropeptides. 2005 Aug; 39(4):439—43. Savontaus E, Conwell IM, Wardlaw SL. Effects of
  244. fasted rats. Brain Res. 2002 Dec 20;958(l):l30-8. Bertile F, Oudart H, Criscuolo F, Maho YL, Raclot T.
  245. Res Commun. 2003 Apr 18;303(4):1 106-13. Tritos NA, Mantzoros CS. Leptin: its role in obesity
  246. and beyond. Diabetologia. 1997 Dec;40( 12): 1371-9. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R,
  247. mice. Science. 1995 Jul 28;269(5223):540-3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold;372:425-32. Hager J, Clement K, Francke S, Dina C, Raison J,
  248. Metab Disord. 1998 Mar;22(3):200-5. CampŞeld LA, Smith FJ, Guisez Y, Devos R, Burn P.
  249. CampŞeld 1995 Science. Chung WK, BelŞ K, Chua M, Wiley J, Mackintosh
  250. Am J Physiol. 1998 Apr;274(4 Pt 2):R985-90. Stefan N, Vozarova B, Del Parigi A, Ossowski V,
  251. Dec;26(12):1629-32. Yiannakouris N, Yannakoulia M, Melistas L, Chan
  252. Sep;86(9):4434-9. Jackson RS, Creemers JW, Ohagi S, RafŞn-Sanson
  253. convertase 1 gene. Nat Genet. 1997 Jul;16(3):303-6. Krude H, Biebermann H, Luck W, Horn R, Brabant
  254. Jun;19(2):155-7. Adan RA, Tiesjema B, Hillebrand JJ, 1a Fleur SE,
  255. Epub 2006 Oct 16. Vaisse C, Clement K, Guy—Grand B, Froguel P. A
  256. Oct; 20(2): 1 13—4. No abstract available. Vaisse C, Clement K, Durand E, Hercberg S, Guy
  257. morbid obesity. J Clin Invest. 2000 Jul; 106(2):253- 62. Mergen M, Mergen H, Ozata M, Oner R, Oner C. A
  258. Metab. 2001 Jul;86(7):3448. Ma L, Tataranni PA, Bogardus C, Baier LJ.
  259. Oct; 53(10):2696-9. Valli-Jaakola K, Lipsanen-Nyman M, Oksanen L,
  260. Metab. 2004 F eb;89(2):940—5. Lubrano-Berthelier C, Cavazos M, Dubem B, Shapiro
  261. mutations. Ann N Y Acad Sci. 2003 Jun;994:49-57. Review. Srinivasan S, Lubrano-Berthelier C, Govaerts C,
  262. Oct;114(8):1158-64. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy;11(5):593-602.Brown AM, Mayfield DK, Volaufova J,
  263. Oct 17;277(1—2):231-8. Beltramo M, Campanella M, Tarozzo G, Fredduzzi S,
  264. Res Mol Brain Res. 2003 Oct 21,1 18(1—2):111-8. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark
  265. No abstract available. Lu XY, Nicholson JR, Akil H, Watson SJ. Time
  266. May 8; 12(6): 1281—4. Small CJ, Liu YL, Stanley SA, Connoley IP,
  267. Disord. 2003 Apr; 27(4):530-3. Goto K, Inui A, Takimoto Y, Yuzuriha H, Asakawa
  268. J Mol Med. 2003 Sep; 12(3):379-83. Makimura H, Mizuno TM, Mastaitis JW, Agami R,
  269. Neurosci. 2002 Nov 73:18. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T,
  270. Biophys Res Commun. 1997 Aug 28; 237(3):629—31. Yang YK, Thompson DA. Dickinson CJ, Wilken J,
  271. :14100-6. Argyropoulos G, Rankinen T, Neufeld DR, Rice T,
  272. :4198-202. Bai F, Rankinen T, Charbonneau C, Belsham DD,
  273. Psychiatry. 2001 May;6(3):325-8. Marks DL, Boucher N, Lanouette CM, Perusse L,